Science, medicine, and the future - Cellular immunotherapy for cancer

被引：28

作者：

Armstrong, AC ^{[1
]}

Eaton, D ^{[1
]}

Ewing, JC ^{[1
]}

机构：

[1] Christie Hosp NHS Trust, Paterson Inst Canc Res, Dept Med Oncol, Canc Res Campaign, Manchester M20 4BX, Lancs, England

来源：

BMJ-BRITISH MEDICAL JOURNAL | 2001年 / 323卷 / 7324期

关键词：

D O I：

10.1136/bmj.323.7324.1289

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

[No abstract available]

引用

页码：1289 / 1293

页数：5

共 17 条

[1]

Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors [J].

AlvarezVallina, L ;

Hawkins, RE .

EUROPEAN JOURNAL OF IMMUNOLOGY, 1996, 26 (10) :2304-2309

[2]

HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia [J].

Bonini, C ;

Ferrari, G ;

Verzeletti, S ;

Servida, P ;

Zappone, E ;

Ruggieri, L ;

Ponzoni, M ;

Rossini, S ;

Mavilio, F ;

Traversari, C ;

Bordignon, C .

SCIENCE, 1997, 276 (5319) :1719-1724

[3]

Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation [J].

Childs, R ;

Chernoff, A ;

Contentin, N ;

Bahceci, E ;

Schrump, D ;

Leitman, S ;

Read, EJ ;

Tisdale, J ;

Dunbar, C ;

Linehan, WM ;

Young, NS ;

Barrett, AJ ;

Clave, E ;

Epperson, D ;

Mayo, V .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (11) :750-758

[4]

Multicenter, randomized, phase III trial of CD8+ tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma [J].

Figlin, RA ;

Thompson, JA ;

Bukowski, RM ;

Vogelzang, NJ ;

Novick, AC ;

Lange, P ;

Steinberg, GD ;

Belldegrun, AS .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) :2521-2529

[5]

Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1 [J].

Gao, LQ ;

Bellantuono, I ;

Elsässer, A ;

Marley, SB ;

Gordon, MY ;

Goldman, JM ;

Stauss, HJ .

BLOOD, 2000, 95 (07) :2198-2203

[6]

ROLE OF BONE-MARROW-DERIVED CELLS IN PRESENTING MHC CLASS I-RESTRICTED TUMOR-ANTIGENS [J].

HUANG, AYC ;

GOLUMBEK, P ;

AHMADZADEH, M ;

JAFFEE, E ;

PARDOLL, D ;

LEVITSKY, H .

SCIENCE, 1994, 264 (5161) :961-965

[7]

HWU P, 1995, CANCER RES, V55, P3369

[8]

Aldesleukin (recombinant interleukin-2) - A review of its pharmacological properties, clinical efficacy and tolerability in patients with renal cell carcinoma [J].

Jeal, W ;

Goa, KL .

BIODRUGS, 1997, 7 (04) :285-317

[9]

RETRACTED: Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids (Retracted article. See vol. 9, p. 1221, 2003) [J].

Kugler, A ;

Stuhler, G ;

Walden, P ;

Zöller, G ;

Zobywalski, A ;

Brossart, P ;

Trefzer, U ;

Ullrich, S ;

Müller, CA ;

Becker, V ;

Gross, AJ ;

Hemmerlein, B ;

Kanz, L ;

Müller, GA ;

Ringert, RH .

NATURE MEDICINE, 2000, 6 (03) :332-336

[10]

MORTON DL, 1993, ANN NY ACAD SCI, V690, P120

← 1 2 →